# evommune.com

> AI-optimized mirror of evommune.com containing 117 pages totalling 128,826 words of clean markdown content, structured data, and semantic HTML. Original source: https://evommune.com. Last updated: 2026-07-26T02:59:29.398Z.

Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG).

## Homepage

- [Evommune | Novel Therapies for Chronic Inflammatory Disease](/content/site-root.html): Evommune is a clinical stage biotechnology company discovering and developing novel therapies to treat immune-mediated chronic inflammatory diseases. (115 words)

## Articles & Blog Posts

- [June 29, 2026 - EX-99.1 - 8-K: Current report | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-286918/evmn-ex99_1-htm.html) (1,135 words)
- [July 16, 2026 - JOINT FILING AGREEMENT - SCHEDULE 13G: Statement of Beneficial Ownership by Certain Investors | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0000919574-26-004453/p15032823_ex99-1-htm.html) (175 words)
- [July 16, 2026 - SCHEDULE 13G: Statement of Beneficial Ownership by Certain Investors | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0000919574-26-004453/primary_doc-html.html) (1,655 words)
- [June 24, 2026 - Patel Jeegar Pravinkumar - 4: Statement of changes in beneficial ownership of securities | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0002092017-26-000007/primarydocument-html.html) (614 words)
- [June 29, 2026 - 8-K: Current report | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-286918/evmn-20260629-htm.html) (833 words)
- [June 29, 2026 - 424B3: Prospectus [Rule 424(b)(3)] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-286924/evmn-2026-june_29_424b3-htm.html) (1,151 words)
- [June 24, 2026 - Drew Janice Suzann - 4: Statement of changes in beneficial ownership of securities | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0002091053-26-000005/primarydocument-html.html) (780 words)
- [July 8, 2026 - Kirsch Arthur S - 4: Statement of changes in beneficial ownership of securities | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001290976-26-000004/primarydocument-html.html) (534 words)
- [July 10, 2026 - Carver Kyle - 4: Statement of changes in beneficial ownership of securities | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001757072-26-000007/primarydocument-html.html) (686 words)
- [June 24, 2026 - Pena Luis C. - 4: Statement of changes in beneficial ownership of securities | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001620548-26-000007/primarydocument-html.html) (673 words)
- [June 3, 2026 - Mcgraw Benjamin F Iii - 4: Statement of changes in beneficial ownership of securities | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001216994-26-000003/primarydocument-html.html) (628 words)
- [June 22, 2026 - 144: Report of proposed sale of securities | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001950047-26-006381/primary_doc-html.html) (257 words)
- [ir/financial-information/sec-filings/rss/index.html](/content/ir/financial-information/sec-filings/rss/index.html) (159 words)
- [March 5, 2026 - EX-4.3 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-093932/evmn-ex4_3-htm.html) (2,666 words)
- [March 5, 2026 - EX-97 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-093932/evmn-ex97-htm.html) (2,252 words)
- [Evommune Presents Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria During Late-Breaker at EADV 2025 Congress :: Evommune, Inc. (EVMN)](/content/ir/news-events/press-releases/detail/85/evommune-presents-full-phase-2-data-for-oral-mrgprx2-inhibitor-evo756-in-chronic-inducible-urticaria-during-late-breaker-at-eadv-2025-congress.html): 




Clinical responses observed in 93 percent of patients at just four weeks in either FricTest Score or Pruritus-NRS, with improvements seen as…... (973 words)
- [March 5, 2026 - EX-19.1 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-093932/evmn-ex19_1-htm.html) (735 words)
- [December 11, 2025 - EX-31.1 - 10-Q: Quarterly report [Sections 13 or 15(d)] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-25-315972/evmn-ex31_1-htm.html) (465 words)
- [March 5, 2026 - EX-32.1 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-093932/evmn-ex32_1-htm.html) (266 words)
- [March 5, 2026 - EX-31.1 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-093932/evmn-ex31_1-htm.html) (465 words)
- [March 5, 2026 - EX-31.2 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-093932/evmn-ex31_2-htm.html) (464 words)
- [December 11, 2025 - EX-32.1 - 10-Q: Quarterly report [Sections 13 or 15(d)] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-25-315972/evmn-ex32_1-htm.html) (263 words)
- [March 5, 2026 - EX-23.1 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-093932/evmn-ex23_1-htm.html) (65 words)
- [May 7, 2026 - EX-31.2 - 10-Q: Quarterly report [Sections 13 or 15(d)] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-211963/evmn-ex31_2-htm.html) (465 words)
- [May 7, 2026 - EX-32.1 - 10-Q: Quarterly report [Sections 13 or 15(d)] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-211963/evmn-ex32_1-htm.html) (265 words)
- [Accessibility Request Form :: Evommune, Inc. (EVMN)](/content/ir/accessibility-request-form/index.html) (190 words)
- [ir/news-events/press-releases/detail/119/evommune-announces-positive-top-line-datafrom-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis.html](/content/ir/news-events/press-releases/detail/119/evommune-announces-positive-top-line-datafrom-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis.html) (1,013 words)
- [Privacy Statement](/content/wp-content/uploads/2023/12/evommune_privacy-statement_for_website-pdf.html) (2,950 words)
- [March 5, 2026 - EX-21.1 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-093932/evmn-ex21_1-htm.html) (22 words)
- [Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update :: Evommune, Inc. (EVMN)](/content/ir/news-events/press-releases/detail/118/evommune-reports-third-quarter-2025-financial-results-and-provides-business-update.html): 


- Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous…... (695 words)
- [Evommune Announces Pricing of its Initial Public Offering :: Evommune, Inc. (EVMN)](/content/ir/news-events/press-releases/detail/116/evommune-announces-pricing-of-its-initial-public-offering.html): 


                
                  PALO ALTO, Calif., Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology…... (609 words)
- [Evommune Announces Commencement of Initial Public Offering :: Evommune, Inc. (EVMN)](/content/ir/news-events/press-releases/detail/115/evommune-announces-commencement-of-initial-public-offering.html): 


                
                  PALO ALTO, Calif., Oct. 30, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology…... (580 words)
- [Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares :: Evommune, Inc. (EVMN)](/content/ir/news-events/press-releases/detail/117/evommune-announces-closing-of-its-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares.html): 


                
                  PALO ALTO, Calif., Nov. 7, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology…... (457 words)
- [Evommune Announces $125 Million Private Placement :: Evommune, Inc. (EVMN)](/content/ir/news-events/press-releases/detail/120/evommune-announces-125-million-private-placement/index.html): 

    PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--
Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage…... (871 words)
- [May 7, 2026 - EX-31.1 - 10-Q: Quarterly report [Sections 13 or 15(d)] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-211963/evmn-ex31_1-htm.html) (465 words)
- [December 11, 2025 - 10-Q: Quarterly report [Sections 13 or 15(d)] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-25-315972/evmn-20250930-htm.html) (61,510 words)
- [Disclaimer :: Evommune, Inc. (EVMN)](/content/ir/disclaimer/index.html) (252 words)
- [Privacy Policy :: Evommune, Inc. (EVMN)](/content/ir/privacy-policy/index.html) (221 words)
- [Past Events :: Evommune, Inc. (EVMN)](/content/ir/news-events/ir-calendar/past/index.html) (85 words)
- [Evommune EVO301 Top-Line Results from Phase 2a Trial in Moderate-to-Severe Atopic Dermatitis :: Evommune, Inc. (EVMN)](/content/ir/news-events/ir-calendar/detail/20260210-evommune-evo301-top-line-results-from-phase-2a-trial-in-moderate-to-severe-atopic-dermatitis.html) (19 words)
- [KOL Webinar Highlighting Role of MRGPRX2 in Migraine :: Evommune, Inc. (EVMN)](/content/ir/news-events/ir-calendar/detail/20260413-kol-webinar-highlighting-role-of-mrgprx2-in-migraine.html) (16 words)
- [May 7, 2026 - 10-Q: Quarterly report [Sections 13 or 15(d)] | Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/content/0001193125-26-211963/evmn-20260331-htm.html) (11,581 words)
- [ir/financial-information/index.html](/content/ir/financial-information/index.html) (37 words)
- [2026 Annual Meeting of Stockholders :: Evommune, Inc. (EVMN)](/content/ir/news-events/ir-calendar/detail/20260602-2026-annual-meeting-of-stockholders/index.html) (12 words)
- [ir/news-events/index.html](/content/ir/news-events/index.html) (185 words)
- [ir/rss-news-feed/index.html](/content/ir/rss-news-feed/index.html) (197 words)
- [Accessibility Statement :: Evommune, Inc. (EVMN)](/content/ir/accessibility-statement/index.html) (252 words)
- [Analyst Coverage :: Evommune, Inc. (EVMN)](/content/ir/stock-data/analyst-coverage/index.html) (120 words)
- [ir/company-info/presentations/rss/index.html](/content/ir/company-info/presentations/rss/index.html) (16 words)
- [Evommune_GUF_2024_EVO756-HV001_Oral_Presentation_22Nov2024_2](/content/wp-content/uploads/2024/12/evommune_guf_2024_evo756-hv001_oral_presentation_22nov2024_2-pdf.html) (805 words)
- [wp-content/uploads/2026/06/evommune_ahs_presentation_role_of_mrgprx2_in_migraine-pdf.html](/content/wp-content/uploads/2026/06/evommune_ahs_presentation_role_of_mrgprx2_in_migraine-pdf.html) (1,022 words)
- [2026 SID EVO301 poster FINAL](/content/wp-content/uploads/2026/05/evommune_2026_sid_evo301_poster-pdf.html) (1,578 words)
- [Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis :: Evommune, Inc. (EVMN)](/content/ir/news-events/press-releases/detail/119/evommune-announces-positive-top-line-data-from-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis.html): 


- Trial met primary efficacy endpoint at week 12



- EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus…... (1,025 words)
- [Slide 1](/content/wp-content/uploads/2025/09/2025_sid_evommune-pdf.html) (1,077 words)
- [In vitro and in vivo efficacy of selective small-molecule PKC-theta inhibitors](/content/wp-content/uploads/2024/12/evommune_ucare_poster-pdf.html) (1,187 words)
- [Slide 1](/content/wp-content/uploads/2025/11/evommune_2025_isds_evo301_poster-pdf.html) (1,150 words)
- [Slide 1](/content/wp-content/uploads/2025/09/042425_aai_2025_evommune-pdf.html) (759 words)
- [Slide 1](/content/wp-content/uploads/2025/09/2025_focis_evommune-pdf.html) (1,041 words)
- [Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights :: Evommune, Inc. (EVMN)](/content/ir/news-events/press-releases/detail/123/evommune-reports-first-quarter-2026-financial-results-and-provides-business-highlights.html): 


‑ Phase 2b top-line data from EVO756 in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) on track for June 2026 and…... (918 words)
- [Slide 1](/content/wp-content/uploads/2026/06/evommune_focis_2026_proteomic_profiling_poster-pdf.html) (950 words)
- [Transcriptional profiling of primary human-skin derived mast cell activation by various MRGPRX2 agonists and inhibition with EVO756](/content/wp-content/uploads/2024/05/evommune_aai_2024_poster_final-pdf.html) (801 words)
- [ir/news-events/press-releases/rss/index.html](/content/ir/news-events/press-releases/rss/index.html) (200 words)
- [Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria :: Evommune, Inc. (EVMN)](/content/ir/news-events/press-releases/detail/124/evommune-announces-top-line-results-from-evo756-phase-2b-trial-in-moderate-to-severe-chronic-spontaneous-urticaria.html): 

- Trial did not meet the primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks
- Evommune to continue…... (653 words)
- [Historical Data :: Evommune, Inc. (EVMN)](/content/ir/stock-data/historical-data/index.html) (302 words)
- [Slide 1](/content/wp-content/uploads/2025/11/evommune_2025_isds_evo756_poster-pdf.html) (712 words)
- [SEC Filings :: Evommune, Inc. (EVMN)](/content/ir/financial-information/sec-filings/index.html) (125 words)
- [wp-content/uploads/2023/12/evo756_poster_pr-pdf.html](/content/wp-content/uploads/2023/12/evo756_poster_pr-pdf.html) (429 words)
- [PowerPoint Presentation](/content/wp-content/uploads/2023/12/evommune_mrgpr_poster_wci_2023-pdf.html) (442 words)
- [Board Committees :: Evommune, Inc. (EVMN)](/content/ir/governance/board-committees/index.html) (151 words)
- [Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights :: Evommune, Inc. (EVMN)](/content/ir/news-events/press-releases/detail/121/evommune-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights.html): 


– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD)



– EVO756 on track to…... (765 words)
- [Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine :: Evommune, Inc. (EVMN)](/content/ir/news-events/press-releases/detail/122/evommune-to-host-kol-webinar-on-april-13-2026-highlighting-the-potential-of-mrgprx2-inhibition-in-migraine.html): 


Company to showcase expansion opportunity for EVO756 (MRGPRX2 Antagonist) into third indication of migraine prophylaxis; Phase 2b study to…... (412 words)
- [Financial Results :: Evommune, Inc. (EVMN)](/content/ir/financial-information/financial-results/index.html) (37 words)
- [Corporate Governance :: Evommune, Inc. (EVMN)](/content/ir/governance/index.html) (92 words)
- [Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Japan](/content/wp-content/uploads/2024/03/18_evommune_maruho_press_release_032024_2-pdf.html) (589 words)
- [Governance Documents :: Evommune, Inc. (EVMN)](/content/ir/governance/governance-documents/index.html) (30 words)
- [Press Releases :: Evommune, Inc. (EVMN)](/content/ir/news-events/press-releases/index.html) (184 words)
- [Quote & Chart :: Evommune, Inc. (EVMN)](/content/ir/stock-data/quote-chart/index.html) (115 words)
- [16_Evommune_Accutar_Biotechnology_Announce_AI Drug_Discovery_Collaboration_(003)_112823](/content/wp-content/uploads/2024/01/16_evommune_accutar_biotechnology_announce_ai-drug_discovery_collaboration_003_112823_2-pdf.html) (428 words)
- [IR Calendar :: Evommune, Inc. (EVMN)](/content/ir/news-events/ir-calendar/index.html) (67 words)
- [Contacts :: Evommune, Inc. (EVMN)](/content/ir/company-info/contacts/index.html) (18 words)
- [FAQ :: Evommune, Inc. (EVMN)](/content/ir/company-info/faq/index.html) (89 words)
- [Email Alerts :: Evommune, Inc. (EVMN)](/content/ir/news-events/email-alerts/index.html) (280 words)
- [Presentations :: Evommune, Inc. (EVMN)](/content/ir/company-info/presentations/index.html) (9 words)
- [Company Info :: Evommune, Inc. (EVMN)](/content/ir/company-info/index.html) (22 words)
- [Slide 1](/content/wp-content/uploads/2025/09/2025_cell-neuro-immune-axis-symposia-poster-pdf.html) (821 words)
- [Evommune | Chronic Inflammatory Disease | Scientific Posters](/content/publications-posters/index.html): View posters presntations for Evommune, a clinical stage biopharma developing novel therapies to treat immune-mediated chronic inflammatory diseases. (951 words)
- [IL-18BP Fusion Protein - Evommune](/content/il-18bp-fusion-protein/index.html) (651 words)
- [Gregory S. Moss, Esq. - Evommune](/content/team/gregory-s-moss-esq/index.html): Gregory S. Moss serves as the Chief Business and Legal Officer, Corporate Secretary and Chief Compliance Officer of Evommune. Prior to Evommune, Greg served as Executive Vice President, General Counsel and Corporate Secretary, Chief Compliance Officer at Kadmon, where he led legal, compliance, and business development operations, culminating in Kadmon’s successful $1.9 billion acquisition by […] (296 words)
- [Evommune | Chronic Inflammatory Disease | Job Openings](/content/job-openings/index.html): Check out job opportunities at Evommune, a clinical stage biopharma developing novel therapies to treat immune-mediated chronic inflammatory diseases. (375 words)
- [Janice Drew, M.P.H. - Evommune](/content/team/janice-drew-mph/index.html): Janice Drew is Chief of Development Operations at Evommune. Janice has over 30 years of experience in clinical development covering early-stage research, Phase 1 through Phase 3 clinical trials, and development activities through the commercialization and life-cycle–management phase of a product. Janice’s expertise lies in program and project-team management, clinical development and operations, and regulatory […] (352 words)
- [Evommune | Chronic Inflammatory Disease | Our Culture](/content/our-culture/index.html): Get to know the culture at Evommune, a clinical stage biopharma developing novel therapies to treat immune-mediated chronic inflammatory diseases. (365 words)
- [Evommune | Chronic Inflammatory Disease | Collaborating](/content/collaborating/index.html): Explore collaboration opportunities with Evommune, a clinical stage biopharma developing new ways to treat immune-mediated chronic inflammatory diseases. (242 words)
- [Evommune | Chronic Inflammatory Disease | Clinical Trials](/content/clinical-trials/index.html): Learn about clinical trials at Evommune, aa clinical stage biopharma developing novel therapies to treat immune-mediated chronic inflammatory diseases. (304 words)
- [Evommune | Chronic Inflammation | MRGPRX2 Antagonist EVO756](/content/mrgprx2-antagonist/index.html): Evommune is a clinical stage biotechnology company developing a MRGPRX2 antagonist to treat immune-mediated chronic inflammatory disease. (517 words)
- [Evommune | Chronic Inflammatory Disease | Approach](/content/approach/index.html): Evommune is a clinical stage biotechnology company discovering and developing novel medicines to treat immune-mediated chronic inflammatory diseases. (209 words)
- [Evommune | Chronic Inflamation Medcines | Disease Focus](/content/disease-focus/index.html): Evommune is a clinical stage biotechnology company discovering and developing novel drugs to treat immune-mediated chronic inflammatory diseases. (206 words)
- [David E. Cohen, M.D., M.P.H. - Evommune](/content/team/david-e-cohen-md-mph/index.html): Dr. David E. Cohen has been a member of the board of directors of Evommune since May 2020. Dr. Cohen has held various positions at the New York University School of Medicine since 1994, including Charles C. and Dorothea E. Harris Professor of Dermatology, Vice Chairman of Clinical Affairs, Chief of Allergy and Contact Dermatitis […] (271 words)
- [Jeegar Patel, Ph.D. - Evommune](/content/team/jeegar-patel-phd/index.html): Dr. Jeegar Patel is the Chief Scientific Officer at Evommune. He brings deep expertise in translational science and nonclinical development, with a track record of advancing innovative therapies from early research through regulatory approval. Prior to joining Evommune, Jeegar served as Senior Vice President, Research and Nonclinical Development at Kadmon, where he held positions of […] (215 words)
- [J. Mark Jackson, M.D. - Evommune](/content/team/j-mark-jackson-md/index.html): Dr. J. Mark Jackson is Senior Vice President, Clinical Development of Evommune. He joins Evommune from his position as a Clinical Professor of Medicine at the University of Louisville. In addition to his academic appointment, he previously served as an advisor to multiple pharmaceutical companies including AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Galderma, Janssen, […] (196 words)
- [Lou Sehl, Ph.D. - Evommune](/content/team/lou-sehl-phd/index.html): Dr. Lou Sehl is Senior Vice President, Technical Operations of Evommune. Lou has more than 30 years of experience in the biotechnology, pharmaceutical, and medical device industries, with a consistent track record of successfully moving projects through all phases of development. Prior to Evommune, he served as Vice President of Manufacturing and Technical Operations at […] (179 words)
- [Evommune | Chronic Inflammatory Disease Therapies | About](/content/about-us/index.html): Evommune is a clinical stage biotechnology company discovering and developing novel therapies to treat immune-mediated chronic inflammatory diseases. (177 words)
- [Eugene A. Bauer, M.D. - Evommune](/content/team/eugene-a-bauer-md/index.html): Dr. Eugene A. Bauer is Co-Founder, Chief Medical Officer and a member of the Board of Directors of Evommune. From 2010 to 2020, Gene was Founder, Chief Medical Officer and member of the Board of Directors of Dermira, a clinical stage dermatology company acquired by Eli Lilly and Company in early 2020. Prior to Dermira, […] (370 words)
- [Sam Chi, M.B.A. - Evommune](/content/team/sam-chi-m-b-a/index.html): Sam Chi serves as Vice President, Commercial and Portfolio Planning at Evommune. He is a seasoned commercial leader with over 20 years of success in various biopharma commercial roles spanning a wide range of therapeutic areas (immunology, hematology, metabolic, respiratory, dermatology, cardiology and oncology). Sam leverages his entrepreneurial DNA and passion for discovering better therapeutic […] (218 words)
- [Rob Hopfner, R.Ph., Ph.D., M.B.A. - Evommune](/content/team/rob-hopfner-rph-phd-mba/index.html): Rob has been a member of the board of directors of Evommune since July 2020 and is a Managing Partner at Pivotal bioVenture Partners, where he focuses on drug discovery and development investments. He has a long track record of working successfully with entrepreneurs to progress novel, important medicines through development and onto the market. […] (135 words)
- [Eugene A. Bauer, M.D. - Evommune](/content/team/eugene-a-bauer-m-d/index.html): Dr. Eugene A. Bauer is Co-Founder, Chief Medical Officer and a member of the Board of Directors of Evommune. From 2010 to 2020, Gene was Founder, Chief Medical Officer and member of the Board of Directors of Dermira, a clinical stage dermatology company acquired by Eli Lilly and Company in early 2020. Prior to Dermira, […] (368 words)
- [Daniel J. Burge, M.D. - Evommune](/content/team/daniel-j-burge-m-d/index.html): Dr. Daniel J. Burge is Senior Vice President, Clinical Development of Evommune. Dan joins Evommune from a consulting practice where he provided strategic advice and tactical implementation for clinical development of small molecules and biologics for biotechnology and pharmaceutical companies. Dan previously worked at Dermira, where he served as Senior Vice President of Clinical Development, […] (268 words)
- [Kyle Carver, M.B.A., C.P.A. - Evommune](/content/team/kyle-carver-mba-cpa/index.html): Kyle Carver serves as Chief Financial Officer of Evommune. Prior to joining Evommune, Kyle was Chief Accounting Officer at Kadmon, a Sanofi Company, where he oversaw all aspects of financial and accounting operations, including Kadmon’s transition to a public company in its 2016 initial public offering through the approval and commercialization of REZUROCK® (belumosudil) in […] (147 words)
- [Derek DiRocco, Ph.D. - Evommune](/content/team/derek-dirocco-ph-d/index.html): Derek DiRocco has been a member of the board of directors of Evommune since October 2024 and is a Partner at RA Capital Management. Derek works on both public and private investments and serves as a member of the board of directors for 89Bio, Mineralys, Werewolf Therapeutics, Acrivon Therapeutics, Rivus Pharmaceuticals, , Forward Therapeutics and […] (134 words)
- [Luis Peña - Evommune](/content/team/luis-pena-2/index.html): Luis Peña is Co-Founder, President & Chief Executive Officer and a member of the Board of Directors of Evommune. Luis has more than 30 years of biotech and pharmaceutical experience with a proven track record of success in the global development of diverse products across multiple therapeutic areas. He is a strategic thinker focused on […] (216 words)
- [Benjamin F. McGraw, III, Pharm.D. (Chair of Board) - Evommune](/content/team/benjamin-f-mcgraw-iii-pharmd-chair-of-board/index.html): Dr. Benjamin F. McGraw has served as Chairman and a member of the Board of Directors of Evommune since October 2020. Dr. McGraw is the Executive Chairman of Perfuse Therapeutics, a clinical-stage biopharmaceutical company committed to reducing the incidence of blindness. He is also a Director at TheraVida, a private pharmaceutical company focused on therapies […] (242 words)
- [Felice Verduyn-van Weegen - Evommune](/content/team/felice-verduyn-van-weegen/index.html): Felice Verduyn-van Weegen has been a member of the board of directors of Evommune since September 2021 and is a Partner at EQT. Felice worked for LSP from 2015 until 2022, when LSP joined forces with EQT and became EQT Life Sciences. Prior to joining LSP, Felice worked as a Consultant at McKinsey & Company […] (116 words)
- [Arthur Kirsch, M.B.A. - Evommune](/content/team/arthur-kirsch/index.html): Arthur Kirsch joined Evommune’s board of directors in October 2025. Mr. Kirsch currently serves as a board member, chairman of Audit Committee, and a member of the Compensation Committee at Liquidia Corporation (Nasdaq: LQDA). Mr. Kirsch is also a director and member of the Audit and Compensation Committees at Atea Pharmaceuticals (Nasdaq: AVIR). Mr. Kirsch […] (188 words)
- [Lorena Riol Blanco, Ph.D. - Evommune](/content/team/lorena-riol-blanco-ph-d/index.html): Dr. Lorena Riol Blanco is Vice President, Biology of Evommune and has a strong record of scientific leadership and extensive biotech experience in translational research, pharmacology, and drug discovery and development. Prior to Evommune, Lorena served as Director of Immunology/Immuno-Oncology at 23andMe where she led multi-departmental disease strategies to advance multiple drug discovery programs for […] (143 words)
- [Luis Peña - Evommune](/content/team/luis-pena/index.html): Luis Peña is Co-Founder, President & Chief Executive Officer and a member of the Board of Directors of Evommune. Luis has more than 30 years of biotech and pharmaceutical experience with a proven track record of success in the global development of diverse products across multiple therapeutic areas. He is a strategic thinker focused on […] (214 words)
- [Evommune | Chronic Inflammatory Disease Therapies | Pipeline](/content/development-pipeline/index.html): Check out the drug pipeline for Evommune, a clinical stage biopharma developing novel therapies to treat immune-mediated chronic inflammatory diseases. (128 words)

## About Pages

- [Evommune | Chronic Infammatory Disease Therapies | Contact](/content/contact/index.html): With its headquarters in Palo Alto, CA, Evommune is a clinical stage biopharma developing new ways to treat immune-mediated chronic inflammatory diseases. (54 words)

## Resources

- [Full Page Index](/index.html): Browse all cached pages with rich metadata
- [About This Cache](/content/about.html): Methodology, technical details, and usage guidelines
- [XML Sitemap](/sitemap.xml): Machine-readable sitemap for crawler discovery
- [Robots.txt](/robots.txt): Crawler directives